Title:
ANTIBODIES BINDING FGFR2B AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/083185
Kind Code:
A1
Abstract:
The application relates to an isolated monoclonal antibody that specifically binds FGFR2B, or an antigen binding portion thereof. The application also relates to a nucleic acid molecule encoding the antibody or antigen binding portion thereof, and an expression vector, a host cell and a method for expressing the antibody or antigen binding portion thereof. The application further relates to a treatment method using the antibody or antigen binding portion thereof, the nucleic acid molecule, the expression vector or the host cell of the disclosure.
Inventors:
LI JIANGMEI (CN)
HU WENQI (CN)
LI FENG (CN)
HU WENQI (CN)
LI FENG (CN)
Application Number:
PCT/CN2023/125402
Publication Date:
April 25, 2024
Filing Date:
October 19, 2023
Export Citation:
Assignee:
BEIJING MABWORKS BIOTECH CO LTD (CN)
International Classes:
C07K16/00; A61K39/395; A61P35/00; C07K16/28; C12N1/21; C12N5/10; C12N15/113; G01N33/53
Domestic Patent References:
| WO2014089193A1 | 2014-06-12 | |||
| WO2018213304A1 | 2018-11-22 | |||
| WO2018129451A2 | 2018-07-12 | |||
| WO2022143728A1 | 2022-07-07 |
Foreign References:
| CA3190569A1 | 2022-04-28 | |||
| CA2915665A1 | 2015-02-05 | |||
| CN104066750A | 2014-09-24 | |||
| CN114901687A | 2022-08-12 | |||
| US20130142802A1 | 2013-06-06 | |||
| AR110819A1 | 2019-05-08 |
Attorney, Agent or Firm:
CHENG & PENG INTELLECTUAL PROPERTY LAW OFFICE (CN)
Download PDF:
Previous Patent: PHARMACEUTICAL COMPOSITION COMPRISING EGFR INHIBITOR
Next Patent: METHOD EXECUTED BY USER EQUIPMENT, AND USER EQUIPMENT
Next Patent: METHOD EXECUTED BY USER EQUIPMENT, AND USER EQUIPMENT